Review Article
Exploring Risk Factors for Follicular Lymphoma
Table 2
Aspects of the medical history and genetic factors associated with FL.
| Exposure | Measured effect (95% CI) | Reference |
| Medical Hx | | |
| Hepatitis history | OR = 0.36 (0.17–0.74) | [37] | History of heart disease | OR = 1.5 (1.0–2.1) | [37] | 3 or more bee stings | OR = 0.79 (0.62–1.0) | [37] | Gallstones | OR = 0.71 (0.33–1.52) | [36] | Hypertension | OR = 0.92 (0.63–1.94) | [36] | DM, no treatment | OR = 2.53 (0.57–11.2) | [36] | Sjogren's syndrome | OR = 3.91 (1.39–11.0) | [42] | History of transfusion | OR = 1.40 (0.87–2.26) | [40] | Medical indication for first transfusion (ref = Trauma) | OR = 3.07 (1.18–7.98) | [40] | Any anesthesia (24+) | OR = 1.49 (0.76–2.91) | [40] | Total number of surgeries (26+) | OR = 1.92 (0.97–3.78) | [40] |
| Pharmaceuticals and vaccinations | | |
| Polio vaccination | OR = 0.54 (0.31–0.92) | [43] | Influenza vaccination | OR= 1.98 (1.23–3.18) | [43] | NSAID use | OR = 0.67 (0.44–1.00) | [37] | Non-insulin diabetes mellitus treatment | OR = 0.29 (0.1–0.82) | [37] | Beta blockers | OR = 2.5 (0.9–7.0) | [37] | DM, no treatment | OR = 2.53 (0.57–11.2) | [36] | DM, oral treatment | OR = 0.46 (0.61–1.35) | [36] | DM, insulin | OR = 0.63 (0.14–2.92) | [36] | Calcium channel blocker use | OR = 1.08 (0.60–1.94) | [36] | Diuretic use | OR = 0.83 (0.48–1.44) | [36] |
| Allergies | | |
| General Hx of allergies | OR = 0.7 (0.5–1.0) | [61] | Hay fever | OR = 0.7 (0.5–1.1) | [61] | Eczema alone | OR =1.9 (1.1–3.4) | [61] |
| Molecular | | |
| SNPs within the MHC region, 6p21.32 | | | rs10484561 | OR = 1.95 (1.72–2.22) | [77] | rs7755224 | OR = 2.07 (1.76–2.42) | [77] | Haplotype HLA-DRB1* 0101-HLA-DQA1*0101-HLA-DQB1* 0501 | OR = 2.07 (1.40–3.06) | [77] | SNPs within DNA repair genes | | | ERCC2 | No association | [78] | XRCC1 | No association | [78] | XRCC3_Rs3212024 | OR = 1.8 (1.1–2.8) | [78] | XRCC3_Rs3212038 | OR = 1.5 (1.0–2.4) | [78] | XRCC3_Rs3212090 | OR = 1.5 (1.0–2.5) | [78] |
|
|